Geosearch / Live Stats / Bug Report / FAQ / About LinkedCT

Outcome: 01b4c01ba8bd968ea28340d83f86ad07 [RDF]

Label 01b4c01ba8bd968ea28340d83f86ad07
Slug 01b4c01ba8bd968ea28340d83f86ad07
Safety issue
Measure Number of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Assessments of Ankylosing Spondylitis Ankylosing Spondylitis (ASAS) 5/6 in Subjects With Adalimumab Exposure Through Week 260
Description The change in ASAS 5/6 was evaluated for the effect of adalimumab on structural damage. ASAS 5/6 criteria is the 20% improvement in 5 out of 6 domains (physical function [BASFI], Total Back Pain, Patient's Global Assessment of Disease Activity, Inflammation [mean of Questions 5 and 6 of the BASDAI], spinal mobility [BASMI], and acute phase reactants [CRP]).
Time frame Weeks 12, 16, 20, 24, 30, 36, 42, 48, 52, 64, 76, 88, 104, 116, 128, 140, 156, 168, 180, 192, 208, 220, 232, 244, and 260
Provenances http://clinicaltrials.gov/show/NCT00195819?displayxml=true
Similars None
Interlinks None